Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
10.3802/jgo.2018.29.e96
Saved in:
Main Authors: | Lee, Matilda X, Tan, David SP |
---|---|
Other Authors: | MEDICINE |
Format: | Review |
Language: | English |
Published: |
KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/206511 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Symptom Clusters in Thai Gynecological Oncology Patients Receiving the First Cycle of Carboplatin and Paclitaxel
by: Bualuang Sumdaengrit, et al.
Published: (2022) -
Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer
by: Huang, R.Y.-J., et al.
Published: (2014) -
LIPID NANOSYSTEM FOR PACLITAXEL AND ALPHA MANGOSTIN: ADDRESSING DRUG RESISTANCE AND NEPHROTOXICITY ASSOCIATED WITH OVARIAN CANCER CHEMOTHERAPY
by: SANTWANA K C
Published: (2022) -
An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
by: Huang, R.Y.-J., et al.
Published: (2014) -
Asian Society of Gynecologic Oncology International Workshop 2018
by: Kong, Tae-Wook, et al.
Published: (2021)